Clinical Trial Update: Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update on dose finding and safety of RVX000222 in subjects with stable coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease

Drugs mentioned

• RVX000222 (apabetalone)

Snippet

Sponsor: Resverlogix Corp | Conditions: Atherosclerosis, Coronary Artery Disease | Phase 2 | Status: COMPLETED